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To identify the underlying reason for the controversial performance of tetracycline (Tet)-controlled regulated gene expression
in mammalian neurons, we investigated each of the three components that comprise the Tet inducible systems, namely
tetracyclines as inducers, tetracycline-transactivator (tTA) and reverse tTA (rtTA), and tTA-responsive promoters (Ptets). We have
discovered that stably integrated Ptet becomes functionally silenced in the majority of neurons when it is inactive during
development. Ptet silencing can be avoided when it is either not integrated in the genome or stably-integrated with basal
activity. Moreover, long-term, high transactivator levels in neurons can often overcome integration-induced Ptet gene
silencing, possibly by inducing promoter accessibility.
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INTRODUCTION
Since the first description of the bacterially-derived Tet-controlled
inducible systems [1–3], gene activation and inactivation has been
achieved in different cell types in animals. The tetracycline-
controlled transactivator-responsive minimal Tet promoters (Ptet/
Ptetbi) [1,4] are activated by the tetracycline transactivator (tTA)
[1] (Fig. 1A-left) and inactivated by tetracycline (Tet-off) or its
derivatives such as doxycycline (Dox). The reverse tTA (rtTA) is
a complementary genetic module uniquely suited for rapid gene
activation by addition of Dox (Tet-on) (Fig. 1A-right) in cultured
cells [1] and in vivo [5,6]. Both systems have been successfully
employed in transgenic mice for studying various biological
functions [7].
As of today, the Tet systems are unique for reversible control
of gene expression in higher eukaryotes [1–3]. Switching gene
expression ‘‘on’’ and ‘‘off’’ is of extreme importance in
understanding the function of genes in phenotypes. This becomes
especially important when studying gene function(s) in the adult
nervous system. Key studies provided the first strong evidence
that the Tet-regulated gene expression can be used to analyze
the involvement of genes in cognition in the mouse [8]. The
successful employment of the a-subunit of CaMKII promoter for
regulating gene expression in the forebrain was first demonstrat-
ed with the Tet-off system [9] and later with the Tet-on system
[10,11].
However, in some studies in the central nervous system (CNS)
employing the Tet-off system, the full reactivation of Tet-
regulated genes after Dox withdrawal was difficult to achieve
once their expression had been suppressed prenatally by Dox
[12–14]. As a consequence, reactivation was slow, expression
patterns changed and expression levels failed to reach their
original maximal values [12–14]. Other studies observed similar
difficulties with the rtTA-dependent gene activation in the mouse
brain [15]. Possible reasons include poor Dox penetrance across
the blood brain barrier (BBB) [15], weak Ptet/Ptetbi activation
in adult mice [16,17] and Ptet/Ptetbi susceptibility to silencing
[18–20].
Here we investigated the regulation of several Tet-responder
genes integrated at different sites in the genome [21–23] and
in an episomal state [24–27] in the mouse. To regulate the
Tet-responder genes, we employed transgenic mice with both
forebrain-specific tTA [9] and rtTA expression (present study) and
monitored responder gene activity by enzymatic activity and
immunohistological analyses of brain slices. We have discovered
that stably-integrated Ptetbi modules in all responder mice become
functionally silenced in the majority of neurons if Ptetbi remain
inactive during development whereas long-term, high transacti-
vator levels in neurons can overcome Ptetbi gene silencing. We also
found that basal Ptet/Ptetbi activity yields permissive conditions for
faster activation/re-activation, possibly by providing better
accessibility of Ptet/Ptetbi to tTA/rtTA.
RESULTS
Forebrain-specific rtTA expression in transgenic
mice can activate Tet-induced gene expression in
some neurons
For controlling transgenic Tet-responder genes, we used activator
mice which express tTA [1,9] and rtTA-M2 [2,28] from the
promoter for aCaMKII [9], which is active mainly in principle
forebrain neurons. We engineered novel tTA and rtTA variants by
replacing the potent activation domain, VP16, with three minimal
activation domains of about 14 amino acids each, abbreviated as
tTA2 and rtTA2-M2 [28]. Next, we generated five rtTA2-
M2CaMK mouse lines. For measuring gene activation, we
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Figure 1. Functional brain specific rtTA mice and tetracycline-induced, rtTA-dependent gene activation in the forebrain. (A) Schematics
depicting the double-positive mice harboring constructs of tTA (left) and rtTA (right) under the control of the aCaMKII promoter and responder
genetic modules under control of bidirectional Tet promoter (Ptetbi) to express Cre recombinase and the firefly luciferase genes. Notice that the tTA
and rtTA activate Ptetbi in the absence and presence of Dox, respectively. (B) Luciferase activity in different brain subregions in double-postive
transgenic mice (rtTA2-M2CaMK-26LC-1) treated with Dox by different delivery routes (black bars, w (water), f (food) and ip (intraperitoneal injection).
For comparison, luciferase activity in double transgenic mice (tTACaMK6LC-1) is also shown (grey bars). Luciferase activity presented on a log scale. (C)
Forebrain-specific expression of Cre recombinase in tTACaMK/LC-1 mice (left). Specific detection of rtTA2-M2 RNA in brain slices of rtTA2-M2CaMK-2
mouse. Gene activation induced for two weeks of 9TB-Dox treatment and Cre signal is visualized by immunohistochemistry (right, insert shows
a magnified image of dentate gyrus).
doi:10.1371/journal.pone.0000533.g001
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employed LC-1 reporter mice [21], which harbor a bidirectional
Tet-promoter cassette (Ptetbi) with genes for luciferase (Luc) and
Cre recombinase (Cre) (Fig. 1A). We treated five rtTA2-M2CaMK
lines crossed to LC-1 with Dox and gene activation was visualized
by both luciferase activity measurements from different brain areas
and Cre immunohistochemistry on fixed brain slices. Robust
transactivation (luciferase activity) was apparent in the olfactory
bulb and low transactivation in the forebrain by three routes of
Dox delivery; water, food and intraperitoneal injection (i.p.)
(Fig. 1B and data not shown). In none of our five rtTA2-M2CaMK
lines could we detect the expected robust forebrain specific gene
activation observed with the tTA system (tTACaMK/LC-1 mice)
[9,14,21] (Fig. 1B and data not shown), despite the fact that rtTA2
mRNA was clearly detectable throughout the forebrain, with
dentate gyrus (DG) granule cells having the highest rtTA2 mRNA
levels in all rtTA2-M2CaMK lines tested (Fig. 1C-middle and Fig.
S1A). One possible explanation for these results was lower
effectiveness of Dox for rtTA-dependent gene activation.
To find a better substitute for Dox, we used a more
hydrophobic Dox derivative, 9-tert-butyl-doxycycline (9TB-Dox),
which when compared to Dox has approximately 10-times higher
binding affinity to the tet repressor (compound available from
Mark Nelson, Paratek Pharmaceutical, Boston, USA, data not
shown) and thus it is also approximately 10-times more effective
than Dox in rtTA2-M2 dependent gene activation in HeLa cells
(data not shown). We found that granule cells of DG, the
subregion with the highest rtTA2 mRNA level (Fig. 1C-middle
and Fig. S1A), showed the best induced Cre expression in all
rtTA2-M2CaMK lines tested, but only a few Cre positive nuclei
were seen in other forebrain regions (Fig. S1B; see Dox-induction
Protocol 1 in Materials and Methods). The influence of high
rtTA2 mRNA levels for Ptetbi gene activation in different brain
regions is clearly apparent in the striatum of rtTA2-M2CaMK-4
mice (Fig. S1A, B). Increasing the treatment time with 9TB-Dox
facilitated rtTA2-M2 dependent gene activation (rtTA2-M2CaMK-
2 mice) in a larger fraction of DG granule cells when tested with
the responder mouse line, LC-1 (Fig. 1C-far right; see Protocol 2
in Materials and Methods), but poorly in the hippocampal CA1
and CA3 fields and in cortex, raising concerns that the BBB might
be impeding Dox availability in the mouse brain.
Dox delivery is not the only limiting factor for lack
of rtTA-dependent gene activation
To investigate whether the BBB was the reason for inefficient Tet-
controlled gene activation in hippocampus and cortex of our
rtTA2-M2CaMK-2 mice, we used the transgenic line G3 which
harbors under Ptetbi control the LacZ and GFP genes [22],
injected into the different brain regions 10 mg of Dox in 1 ml (0.7%
NaCl) and tested for reporter gene activation. Seven days after
Dox injection, GFP expression was induced mainly in DG granule
cells on the injected side of the brain (Fig. 2A), but only in a few
cortical neurons. These results demonstrate that Ptetbi activation in
G3 responder mice failed even when Dox availability was not
a limiting factor.
Our result also finds support from Dox-treatment of organo-
typic hippocampal slices derived from rtTA2-M2CaMK -2/LC-1
mice. We again used the Ptetbi–directed Cre expression of the
responder LC-1 to exclude line specific effects. Dox added to the
culture medium activated Ptetbi expression only in DG granule
cells but again not in CA1/CA3 neurons (Fig. 2B). Ptetbi activation
was not detected without Dox. These results suggest that the
responder genes controlled by Ptetbi may become silenced in
neurons during development.
For Ptetbi re-activation, incomplete suppression of
tTA-dependent gene expression is necessary and
sufficient
We described previously reversible Ptetbi regulation in neurons in
the brains of tTACaMK/LC-1 mice [21]. Such a reversible Ptetbi
regulation should not be possible if transcriptionally inactive Ptetbi
become silenced. Therefore, we analyzed in the brains of
tTACaMK/LC-1 [21] mice the transcriptional activity of Ptetbi
after switch-off by Dox treatment. For a detailed examination we
treated adult mice (P60) with different Dox concentrations (2 to
2000 mg/ml in drinking water) and measured down-regulation of
Ptetbi-controlled luciferase expression by bioluminescence imaging
of brain explants and biochemical measurements of whole brain
extracts (Fig. 3A). Increasing Dox concentrations down-regulated
Luc activity in a graded manner. High Dox concentration (2 mg/
ml) reduced Luc activity by approximately 95% but not to
background levels observed in LC-1 mice not carrying the
aCaMKII promoter tTA transgene (Fig. 3A). To bypass the
BBB, we treated throughout gestation newborn tTACaMK/LC-1
mice with 2 mg/ml of Dox in the drinking water (Fig. 3B) when
BBB does not exist and Dox availability into brain tissue is not
a limiting factor and found complete suppression of gene activity
in the brain of newborn pups. To rule out line specific effects, we
also employed a different aCaMKII promoter tTA line, CN12
[29], and again found incomplete gene inactivation by Dox
(2 mg/ml, 3 weeks) (Fig. 3B). These results indicate that a Dox
concentration needed for complete Ptetbi suppression cannot be
reached in the brain by including 2 mg/ml of Dox in the drinking
water. Since complete suppression of tTA-dependent gene activity
in cultured mammalian cells [1] requires 10 ng/ml of Dox, it
seems plausible that the effective Dox concentration in brain tissue
in vivo will not exceed 10 ng/ml.
Figure 2. Direct Dox delivery to brain tissues. (A) Induced gene
expression in the rtTA2-M2CaMK-2/G3 mouse by direct Dox injection into
brain regions in vivo, DG granule cells (left) and cortex (right). (B) Gene
expression in organotypic slices of rtTA2-M2CaMK-2/LC-1 mice either
without Dox (left) or treated with Dox (right). Scale bars, 200 mm.
doi:10.1371/journal.pone.0000533.g002
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Our results suggest that persistent basal Ptetbi activity prevents
the Ptetbi locus from being silenced. Transcriptional activity might
keep the chromatin locus ‘‘open’’, thus providing permissive
conditions for gene re-activation upon removal of Dox.
Episomal Ptetbi responders are activatable in rtTA2-
M2CaMK-2 mice
To provide direct proof that chromosomally-inserted Ptetbi
become transcriptionally inaccessible for functional tTA/rtTA
dependent gene expression, we delivered by stereotactic injection
recombinant adeno-associated virus (rAAV) carrying the Ptetbi
responder genes Cre and GFP into the hippocampus and cortex of
rtTA2-M2CaMK-2 mice. As AAV remains in an episomal state
[24,25], we asked whether that non-integrated state might provide
a permissive condition for Ptetbi, possibly by increasing promoter
accessibility [30]. Indeed, we detected in the cortex and
hippocampus of rtTA2-M2CaMK-2 mouse brains after viral
injection with rAAV-Ptetbi-GFP/Cre robust GFP expression by
9TB-Dox (i.p; 1.5 mg/injection, every 48 hours, 10 days). A large
number of cortical neurons were visible by live GFP fluorescence
and in fixed brain slices after 10 days of 9TB-Dox treatment
(Fig. 4A, see Protocol 2 in Materials and Methods). Mice not
treated with 9TB-Dox did not show Ptetbi activation (data not
shown). Because non-integrated rAAV-Ptetbi-GFP/Cre, without
tTA, have basal promoter activity, we used low virus titers to
reduce background signal (data not shown). We estimate that 9TB-
Dox induced, rtTA2-M2 dependent gene activation of rAAV-
Ptetbi-GFP/Cre can be as high as 20-fold, as determined by two-
photon imaging of GFP fluorescence in fixed brain slices (data not
shown). Further, we find that gene activation occurred rapidly
within hours after a single pulse of 9TB-Dox by i.p. injection
(Fig. 4B).
These results reveal two key points: first, episomal rAAV vectors
are highly permissive for gene activation in neurons in vivo. Second,
neuronal rtTA2-M2 levels in rtTA2-M2CaMK-2 mice are func-
tionally sufficient for rAAV-Ptetbi activation. Therefore, it seems
most reasonable to conclude that chromosomally-integrated Ptetbi
modules are functionally silenced in neurons.
Prolonged high tTA expression overcomes Ptetbi
silencing in neurons
It is well known that the potent transcriptional activator derived
from Herpes Simplex virus, VP16, has anti-silencing gene activity
[30–32]. Since tTA2 [28] is equipped with three minimal
activation domains with similar properties, we investigated
whether strong tTA expression in neurons of the responder mice
would overcome Ptetbi silencing. Therefore, we delivered either
tTA2 or rtTA2-M2 under control of the human synapsin
Figure 3. Incomplete gene suppression by Dox. (A) Dox-controlled, tTA-dependent gene inactivation of luciferase activity detected in intact brain
and lysates from double-positive transgenic mice (tTACaMK6LC-1), either untreated or treated with different Dox concentrations in the drinking water
for three weeks. Single-positive transgenic LC-1 mouse brain also shown as a control (far left). (B) Two different strains of double-positive mice,
(tTACaMK6LC-1 and tTACN126LC-1), were used to measure luciferase activity in the forebrain (displayed on a linear scale), either untreated or Dox-
treated (2 mg/ml of Dox in the drinking water) for three weeks. Also, luciferase activity was measured from the forebrain in newborn embryos treated
with Dox throughout development (tTACaMK6LC-1, far right). Scale bar, 100 mm.
doi:10.1371/journal.pone.0000533.g003
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promoter (hSyn) by injecting rAAV-hSyn-tTA2 into cortex and
hippocampus of Tet-responder line MTH-Cg2-7 that showed
robust Ptetbi promoter activity in the genetic background of
tTACaMK mice (Fig. S2A). Two weeks after rAAV infection of
MTH-Cg2-7, tTA2 expression was apparent in cortical neurons
but Ptetbi activation was observed in only a very few neurons as
revealed by GFP immunostaining (Fig. 5A-upper right panel and
Fig. 5C). Similar results were found for eight different ‘‘tight’’ Tet-
responder mouse lines. In total we analyzed approximately
100,000 neurons on serial sections (6 slices per mouse and 2
mice/line) immunostained for GFP and tTA2. For eight different
‘‘tight’’ Tet-responders, we found that after two weeks of virus
infection, GFP gene activation was apparent in only a small
fraction of neurons in CA1, DG and cortex, whereas after three
weeks and beyond GFP activation was nearly complete in CA1
and DG, but remained incomplete in cortical neurons (Fig. 5C
and data not shown). Next, we wanted to determine whether long-
term expression of tTA2 would overcome Ptetbi silencing.
Consistent with the role of the transcriptional activation domain
of VP16 in gene un-silencing [30–32], we found that high tTA2
levels in neurons gradually increase Ptetbi activation over time and
thus Ptetbi un-silencing (Fig. 5A-lower panel and C). However, in
mouse line MTH-Cg2-19 with basal Ptetbi activity [23] we
observed widespread GFP expression in CA1, DG and cortical
subregions already after two weeks of viral tTA2 expression
(Fig. 5B-upper panel), and 9TB-Dox induced gene activation in
MTH-Cg2-19 mice was also apparent to similar extend when
rtTA2-M2 was delivered by rAAV (Fig. 5B-lower panel). These
results indicate a more permissive nature of Ptetbi in the MTH-
Cg2-19 line (Fig. 5B). Again, GFP expression was incomplete in
a majority of cortical neurons (,40%) with lowest response
observed in cortical layer 4 (Fig. 5C). It is conceivable that
different neuronal populations differ in their requirements for gene
re-activation of silenced Ptet-controlled genes.
Although viral-mediated tTA/rtTA delivery into neurons of
MTH-Cg2-19 mice identifies this line as ‘‘more permissive’’ than the
other eight responder lines tested so far, 9-TB-Dox induced gene
activation in MTH-Cg2-19/rtTA2-M2CaMK-2 double-positive mice
remained restricted to DG granule cells (Fig. S3A). It is possible that
basal Ptetbi gene activity in neurons of MTH-Cg2-19 mice is still
insufficient and rtTA-M2 levels provided by rtTA2-M2CaMK-2 mice
are not high enough for un-silencing. As a control, we can show that
MTH-Cg2-19 mice can be activated in a forebrain-specific manner
in crosses with tTACaMK mice (Fig. S3B, also see Fig. S2B).
Altogether, we have demonstrated here that prolonged high
tTA2 expression in responder mice can induce Ptetbi re-activation,
possibly due to the counter-silencing effects of the transcriptional
activator [30–32].
DISCUSSION
Over the last 10 years, the reported performance of the tTA
system for reversible control of gene expression in neurons has
been consistently remarkable. For example, an activator line
driving tTA expression in principle neurons under the control of
the aCaMKII promoter, tTACaMK [9], has been elegantly used to
reversibly regulate the expression of various responder transgenes
for studying synaptic plasticity and learning and memory [9,12].
Targeted expression of the tTA protein specifically in CA1
principle neurons has further revealed a direct link between
selective neuronal circuit function(s) and memory consolidation
[33]. On the other hand, in spite of a few reported successes
[10,11,34], others report difficulties with the Dox-induced, rtTA-
dependent gene expression in neurons [15,16,18]. The controver-
sial performance of the rtTA system in neurons prompted us to
systematically examine individual components of the Tet system,
namely Dox availability across the BBB, rtTA levels and Ptet/Ptetbi
activation.
We have clearly demonstrated here that lack of gene activation by
rtTA in neurons in adult mice is mainly due to the silencing of stably-
integrated Ptet/Ptetbi modules. By combining rtTA2-M2 and an
improved Dox derivative, 9TB-Dox, we have provided strong
evidence for fast and robust gene activation in neurons when
episomal Ptetbi modules had been introduced into the brain of our
rtTA2-M2CaMK-2 mice (live GFP fluorescence, Fig. 4A). Consis-
tently, we could not achieve gene activation in eight different ‘‘tight’’
Tet-responder lines tested with tTA2 delivered via rAAV in vivo into
brain areas (Fig.5A-upper panel, Fig. 5C and data not shown). This
indicates that the poor activation of Ptetbi responder genes in the
mouse brain is neither due to the poor penetration of Dox across the
BBB nor to low rtTA levels in neurons, but is most likely due to
silencing of the stably-integrated Ptetbi in the genome.
We asked whether there are specific environmental conditions
which would prevent the Ptetbi locus from becoming silenced.
Towards this question, we found that unlike ‘‘tight’’ responders
where Ptetbi modules integrated in a genomic site with no intrinsic
activity, Ptetbi integrated in a genomic site with basal Ptetbi activity
will keep the locus permissive. We were able to identify one such
Figure 4. Episomal Ptetbi responder gene activation in rtTA2-M2
CaMK-
2 mice. (A) rAAV-Ptetbi-GFP
venus/Cre infected into the brain of rtTA2-
M2CaMK-2 mice and robust Ptetbi gene activation (live GFP fluorescence)
was clearly apparent throughout the infected sites (cortex, Cx, and
hippocampal layers CA3 and CA1) after 10 days of treatment with 9TB-
Dox. (B) Rapid gene activation is also apparent within hours of 9TB-Dox
treatment. Scale bars, 100 mm.
doi:10.1371/journal.pone.0000533.g004
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mouse line, MTH-Cg2-19 [23], which we label as ‘‘permissive
line’’ because tTA-dependent Ptetbi activation in these mice occur
earlier compared to ‘‘tight’’ lines (compared Fig. 5A-upper panel
with Fig. 5B-upper and lower panels, also see Fig. 5C). These
observations strongly support the hypothesis that basal Ptetbi
activity can keep the chromatin locus accessible for tTA/rtTA
dependent gene activation.
Consistent with this idea, we have also discovered that basal
Ptetbi activity is essential for achieving multiple cycles of gene
inactivation by Dox and re-activation upon Dox withdrawal in
tTA-activator/Ptetbi-responder mice [9,21,35]. Previously, we
showed that tTA-dependent gene expression in tTACaMK/LC-1
mice begins prenatally, at embryonic day 12.5 (E12.5) [14]. It is
possible that early tTA expression in neurons during development
activates Ptetbi and antagonizes silencing. Moreover, even when
tTACaMK/LC-1 and tTACN12/LC-1 mice are kept on Dox (2 mg/
ml) for weeks, luciferase activity is not completely suppressed to
levels observed in single-positive LC-1 mice (Fig. 3A, B), rendering
Figure 5. Un-silencing of Ptetbi in neurons. (A) rAAV mediated high tTA expression in cortical neurons of responder mice (MTH-Cg2-7) after two
weeks (upper panel) and eight weeks (lower panel). (B) MTH-Cg2-19 mice with ‘‘basal’’ Ptetbi activity infected either with tTA2 (upper panel) or with
rtTA2-M2 (lower panel). Serial brain sections were stained for tTA/rtTA2-M2 (left panel) and induced GFP expression (right panel). (C) Fraction of GFP-
positive/tTA-positive neurons in different brain subregions (cortical layers, CA1 and DG) of different responder lines over time. Day post infection
(DPI). Scale bars, 250 mm.
doi:10.1371/journal.pone.0000533.g005
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the Ptetbi locus permissive in neurons and enabling gene re-
activation upon Dox removal [9,21].
How would one create conditions to unlock the silencing in
‘‘tight’’ Tet-responder lines? We found that even high tTA2
expression can not activate Ptetbi in neurons two weeks after rAAV
infection but long-term (three weeks and beyond) high tTA2 levels
in neurons can overcome Ptetbi gene silencing (Fig. 5A-lower
panel, C), perhaps involving chromatin remodeling by transcrip-
tional activation domain in tTA/rtTA modules [28,36]. We have
also found that tTA2-dependent Ptetbi un-silencing is nearly
complete in neurons of hippocampus, particularly in the DG
subregion but incomplete in the cortex (Fig. 5C). Why about 40%
of cortical neurons remain resistant to gene activation even in the
presence of high tTA2 levels is not clear. It is conceivable that
diverse neuronal types might have different requirements for gene
activation, silencing and un-silencing (or re-activation). In our
studies, gene activation appears permissive in olfactory receptor
neurons and DG granule cells, consistent with previous observa-
tions [37]. These cell types might be generally more resistant to
gene silencing, possibly because they regenerate throughout life.
To reveal molecular changes which might orchestrate Ptet/Ptetbi
silencing, we performed DNA methylation analyses on Ptetbi, but
were unable to correlate the observed fraction of DNA
methylation of genome-integrated Ptetbi with the fraction of Ptetbi
silencing in neurons. We also failed to find a significant difference
in DNA methylation in brain and liver tissues (data not shown).
Individual DNA sequencing of clones of Ptetbi from brain tissue
revealed that only 4% of the clones show strong methylation over
the entire sequence of Ptetbi (Fig. S4, also see ‘‘Notes on Ptetbi
methylation’’, Fig. S5). This result does not account for about
100% of cortical neurons (representing approx. 60% of total DNA
pool) for which we observe strong functional Ptetbi silencing
(Fig. 1C-far right and Fig. S1B, Fig. 5A-upper panel and 5C). The
simple fact that we have identified a strongly methylated Ptetbi in
cortical genomic DNA hints at epigenetic control mechanisms in
certain cell types in the brain. Therefore, we conclude that for
Ptetbi silencing other mechanisms, besides DNA methylation, are
likely to be more relevant, such as chromatin-controlled promoter
accessibility to transcriptional factors [30].
We thus favor the idea that different cell types might have
different degrees of accessibility to Ptet/Ptetbi [30]. What
determines whether a gene is either silenced permanently or is
allowed to un-silence by an environmental signal? Of special
interest is the ability of immediate-early-genes (IEGs), including c-
fos and arc, to become transcriptionally activated by a specific
stimulus [38]. It is well known that IEGs have different levels of
basal transcriptional activity in different cell types in the
‘‘uninduced state’’ [38]. It is still unclear whether basal
transcriptional activity of IEGs provide a permissive condition
for gene activation in certain neuron types. It is tempting to
speculate that basal IEG activity might be needed for activity-
induced rapid gene activation in neurons.
Our studies have delineated the necessary conditions for
reversible control of gene expression in neurons. First, we have
shown that the stably-integrated Ptetbi becomes silenced, provided
it is inactive during development, and that high tTA/rtTA levels
in neurons allow for Ptetbi un-silencing over time. Second, we have
introduced an alternative approach for reversible control of gene
expression in neurons by using episomal responder delivery via
rAAV. This combinatorial genetic approach of combining viruses
with genetically altered mice is eminently suitable for targeting cell
type specific gene expression in select brain subregions. For
example, in combination with in vivo 2-photon imaging [23,39], it
is likely to facilitate direct visualization of functional neuronal
circuits, by employing genetically-encoded fluorescent biosensors
as reporters of cell physiology such as for calcium [40,41] and
synaptic transmission [42].
The defined transcriptional elements of the Tet systems
described here should be useful to probe mechanistic issues in
regard to chromatin-remodeling in the mammalian neurons and
help in identifying factors that modulate promoter silencing and
un-silencing in neurons.
MATERIALS AND METHODS
Generation of transgenic mice
Novel synthetic rtTA variants, rtTA2-M2, and, in addition,
rtTA2-nM2, containing a simian virus 40 (SV40) 13 amino acid
nuclear localization signal (nls) with optimal codons, lacking
putative splice acceptor/donor sites [28] and equipped with
minimal activation domains [36] were used to produce transgenic
mice. Coding sequences for transactivators (rtTA2-M2 and rtTA2-
nM2) and the SV40 polyadenylation signal were placed under the
aCaMKII promoter fragment [9] resulting in two constructs:
aCaMKII-rtTA2-M2 and aCaMKII-rtTA2-nM2. Purified DNA
fragments devoid of vector backbone were injected into mouse
pronuclei to generate transgenic mouse lines in the facility of
Zentrum fuer Molekulare Biologie at the University of Heidelberg.
Newly generated mouse lines for each rtTA variant subtype,
rtTA2-M2 and rTA2-nM2, have been cataloged as rTA-M2CaMK-
2, rTA-nM2CaMK-4 rTA-nM2CaMK-6 rTA-nM2CaMK-7 and rTA-
nM2CaMK-8. In this study, we have also used the forebrain-specific
aCaMKII driven tTA expressing mouse lines; the tTACaMK (line
B) [9] and the tTACN12 [29]. Different responder mouse under
control of Ptetbi are all indicated here first by the line name and
the two genes in parentheses; LC-1 (luciferase and Cre
recombinase) [14,21], G3 (GFP and lacZ) [22], MTH-Cg2-7
(camgaroo-2 and firefly luciferase), MTH-Cg2-19 (camgaroo-2
and firefly luciferase) and MTH-IP-1 (inverse pericam and firefly
luciferase) [23]. All procedures were performed with the German
federal guidelines for animal experiments (Licence no. 35-
9185.8116-4102, Tubingen, Germany).
In situ RNA hybridization
In situ hybridization studies using 35S-labeled oligonucleotide
probes were performed according to the method described
previously [43]. Saggital 10 mm thick frozen brain slices were
prepared by cryostat sectioning from individual animals derived
from five different independent rtTA mouse lines. Three
oligonucleotide sequences from different coding regions of
synthetic tTA/rtTA were hybridized to different brain slices in
parallel. All probes gave similar results. The oligonucleotide
sequences used are indicated below. Data shown in Fig. 1C-middle
and Fig. S1A is from oligo#2.
tTA/rtTA-Oligo#1: 59-TTTAGCTGTTTCTCCA-
GGCCACATATGATTAGTTCC-39
tTA/rtTA-Oligo#2: 59-AGCTGATTTTCCAGGGT-
TTCGTACTGTTTCTCTGTT-39
tTA/rtTA-Oligo#3: 59-ATAGAATCGGTGGTAGG-
TGTCTCTCTTTCCTCTTTT-39
To assess for specificity and rule out non-specific labeling of
brain sections, each radiolabeled oligonucleotide was hybridized
with a 100-fold excess of unlabelled oligonucleotide. Images were
processed after 4 week exposure using Biomax MR (Kodak) X-ray
films.
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Routes of Dox delivery
Animals were singly housed in a cage in order to avoid
competition for water and food intake. Doxycycline (4-[Dimethy-
lamino]-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahy-
droxy-6-methyl-1,11-dioxo-2-naphthacenecarboxamide; Sigma-
Aldrich, St. Louis, Missouri, United States) was administered to
animals by three different delivery routes; drinking water (2 mg
per milliliter plus 5% sucrose, fresh every 3 days), food (20 mg per
gram plus 20% sucrose, fresh every 3 days) and intraperitoneal
injection (i.p) (Dox; 4 mg/300 mL, 9TB-Dox; 1.5 mg per 300 mL).
Protocol 1: 9TB-Dox injected every 12 hours. Protocol 2: 9TB-
Dox injected every other day. Experiments were performed
according to animal guidelines (Licence no. 35-9185.82/A-49106
Karlsruhe, Germany).
Quantifying gene activity and expression patterns
Mouse brains were saggitally cut into two halves. One half was
fixed in 4% paraformaldehyde, the other half was used for the
measurement of luciferase activity in different brain subregions.
Fixed brain slices were cut to a thickness of 75–100 mm using
vibratome (VT 1000S; Leica Instruments, Wetzlar, Germany).
Luciferase activity was measured from brain extracts as described
previously [6,21] and immunohistochemistry for Cre recombinase
and b-galactosidase was performed also as described previously
[14,21]. Green fluorescence protein (GFP) [44] was visualized in
fixed slices either by live fluorescence imaging or by immunohis-
tochemistry using GFP-specific polyclonal rabbit antibodies
(Clontech, Mountain View, California, USA) (Krestel et al.
2001) and the DAB peroxidase system (Vectastain ABC Kit;
Vector Laboratories, Burlingame, California, USA) or by direct
observation of fluorescence with an upright microscope (Zeiss,
Oberkochen, Germany) equipped with GFP filters. Dual labeling
of neurons for both tTA and GFP was not possible because we
needed to employ antigen-specific polyclonal rabbit antibodies for
high sensitivity detection of both tTA and GFP.
Organotypic hippocampus slices
Approximately 300 mm thick hippocampus organotypic slice
cultures from P3-P5 pups were prepared as described [45] (double
transgenics, rtTA-M2CaMK-26LC-1, positively identified by
genotyping) and were cultured at 7% CO2. Doxycycline treatment
(1 mg/ml) was started on the day of slicing and was continued for 4
days. Cultures were then fixed for 15 minutes in 4% para-
formaldehyde and stained with an anti-Cre rabbit polyclonal
antibody (1:1000) and a Cy3-labeled secondary antibody (1:250,
Dianova, Hamburg, Germany). In Fig. 2B, images are presented
in grey scale.
Adeno-associated viral mediated gene transfer into
mouse brain tissues
Recombinant adeno-associated virus (rAAV) [27] equipped with
the Ptetbi [4] and harboring synthetic Cre recombinase (miniCre)
[46] and a GFP-variant (Venus) [47] was used to generate the
plasmid rAAV-Ptetbi-GFP/Cre. Plasmids, rAAV-Ptetbi-GFP/Cre,
rAAV-hSyn-tTA and rAAV-hSyn-rtTA2-nM2 were individually
co-transfected with pDp1, pDp2 (ratio: 3:1) helper plasmids [48] in
HEK293 cells. Seventy-two hours after transfection, HEK293 cells
were collected and packaged viruses were released by repeated
freeze-and-thaw on dry-ice-ethanol bath. Viruses were purified by
pre-casted 5ml Heparin columns (Amersham, Freiburg, Ger-
many). Infectious virus titers were determined in primary neuron
cultures. Viruses were delivered through thin glass pipettes to
specific brain sites by stereotaxic injection using the SAS75
stereotaxic alignment system with combination of EM70G
manipulator (Kopf Instruments, Germany). Infected animals were
kept for 14–21 days before analysis of brain tissues. All
experiments were carried out according to the biosafety guidelines
specified in the German GenTSV (Regierungprasidium Tubinger,
A2:35-9185.8/10-56105).
Sodium bisulphite conversion, PCR amplification
and sequencing
Genomic DNA was prepared according to standard procedures.
Sodium bisulphite treatment of genomic DNA was performed as
described previously [49] with minor modifications. Since
methylated cytosines have the same base-pairing characteristics
as unmethylated cytosines, DNA is chemically modified to
distinguish between the two species. Purified genomic DNA was
treated with sodium bisulphite, resulting in the conversion of
unmethylated cytosine to uracil. In a subsequent PCR uracil is
replicated as thymine. Methylated cytosines are protected from
conversion and remain as cytosines. Thus, detection of a ‘‘C’’ in
a sequencing reaction reflects methylation at that site whereas
detection of a ‘‘T’’ indicates no methylation. PCRs were performed
on MJ Research thermocyclers (Waltham, Massachusetts, United
States) in a final volume of 25 ml containing 16PCR Buffer, 1 U /
Taq/ DNA polymerase (Qiagen), 200 mM dNTPs, 12.5 pmol each
of forward and reverse primers, and 7 ng of bisulphite-treated
genomic DNA. The amplification conditions were 95uC for 15 min
and 40 cycles of 95uC for 1 min, 55uC for 45 sec and 72uC for 1 min
and a final extension step of 10 min at 72uC. PCR products were
purified using ExoSAP-IT (USB Corp., Cleveland, Ohio, United
States) and sequenced employing the PCR primers and the ABI Big
Dye Terminator v1.1 cycle sequencing chemistry (Applied Biosys-
tems, Foster City, California, United States) followed by capillary
electrophoresis on an ABI 3100 genetic analyzer. AB1-files were
interpreted using ESME, which normalizes sequence traces, corrects
for incomplete bisulphite conversion and allows for quantification of
methylation signals. The following primers were used both for PCR
amplification of bisulfite converted genomic DNA and sequence
reactions:
Amp806 fw: 59-TATAGTTTTATGTAGTTGTTT-
TTTAG-39 and
Amp806 rev: 59-AATAAATTAAACACCTTCCTC-39.
PCR products were cloned using the TOPO TA Cloning Kit
(Invitrogen). Sequencing was carried out using the M13 Forward
and M13 Reverse primers by 3100 Genetic Analyzer (Applied
Biosystem). All bisulphite sequencing experiments were performed
in duplicate and sequencing data was analyzed using SeqMan
(Lasergene, DNASTAR, USA). The conversion rate was approxi-
nately 95%. We have fully sequenced and characterized 71 clones.
SUPPORTING INFORMATION
Figure S1 Expression of rtTA mRNA and Cre protein in the
brain of different mouse lines. (A) Detection of rtTA-M2 mRNA in
the brain slices of different rtTA2-M2CaMK mouse lines. Specific
signal detected with radiolabeled oligonucleotides for rtTA2-M2
(left) and non-specific signal (right). (B) 9TB-Dox induced, rtTA-
dependent Cre expression in different brain regions (rtTA2-
M2CaMK lines crossed to LC-1 responders). Abbreviations: Cx
(cortex), Hi (hippocampus), Ce (cerebellum), St (striatum) and Ob
(olfactory bulb). Scale bars, 2 mm (A) and 1 mm (B).
Found at: doi:10.1371/journal.pone.0000533.s001 (6.30 MB TIF)
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Figure S2 Forebrain-specific, tTA-dependent gene activation in
responder mice MTH-Cg2-17 and MTH-Cg2-19. (A, B) single-
positive (without tTACaMK) (left panel) and double-positive (with
tTACaMK) (right panel).
Found at: doi:10.1371/journal.pone.0000533.s002 (8.22 MB TIF)
Figure S3 9TB-Dox induced, rtTA-dependent gene activation
in MTH-Cg2-19. (A) with rtTA-M2CaMK-2 and (B) with
tTACaMK. Scale bar, 500 mm.
Found at: doi:10.1371/journal.pone.0000533.s003 (9.49 MB TIF)
Figure S4 Methylation of the Ptetbi. (A) The bidirectional
tetracycline-responsive promoter (Ptetbi) is depicted and CpG sites
are indicated as open circles. (B) Sequence analysis of 71 individual
clones is plotted with the number of methylated CpG detected (y-
axis) against the number of independent clones (x-axis). The actual
data set collected is based on methylation detected from
sequencing (red) and the calculated data is based on 5% C-to-T
conversion loss (blue). Three of seventy-one clones (4%) are
strongly methylated.
Found at: doi:10.1371/journal.pone.0000533.s004 (0.47 MB TIF)
Figure S5 Notes on Ptetbi methylation analyses.
Found at: doi:10.1371/journal.pone.0000533.s005 (0.02 MB
DOC)
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